GeneDx Holdings Corp. (NASDAQ:WGS – Get Free Report) has been assigned a consensus rating of “Moderate Buy” from the six analysts that are covering the stock, Marketbeat reports. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $72.33.
WGS has been the topic of a number of recent research reports. The Goldman Sachs Group raised their price objective on GeneDx from $70.00 to $80.00 and gave the stock a “neutral” rating in a research note on Wednesday, February 19th. TD Cowen lifted their price objective on shares of GeneDx from $75.00 to $118.00 and gave the company a “buy” rating in a research note on Tuesday, January 7th.
Check Out Our Latest Stock Report on GeneDx
Insider Activity at GeneDx
Hedge Funds Weigh In On GeneDx
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Principal Financial Group Inc. bought a new position in GeneDx during the third quarter worth $604,000. GSA Capital Partners LLP acquired a new stake in GeneDx during the 3rd quarter worth about $322,000. Royce & Associates LP bought a new position in shares of GeneDx in the 3rd quarter worth about $1,201,000. Connor Clark & Lunn Investment Management Ltd. acquired a new position in shares of GeneDx in the 3rd quarter valued at about $2,547,000. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of GeneDx by 304.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 147,034 shares of the company’s stock valued at $6,240,000 after purchasing an additional 110,666 shares in the last quarter. 61.72% of the stock is owned by institutional investors and hedge funds.
GeneDx Stock Performance
WGS opened at $94.46 on Friday. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. The company has a market capitalization of $2.65 billion, a PE ratio of -48.19 and a beta of 1.91. The business has a fifty day simple moving average of $84.69 and a 200 day simple moving average of $70.37. GeneDx has a 1 year low of $7.72 and a 1 year high of $115.60.
GeneDx (NASDAQ:WGS – Get Free Report) last released its quarterly earnings results on Tuesday, February 18th. The company reported $0.70 EPS for the quarter, topping analysts’ consensus estimates of $0.04 by $0.66. The business had revenue of $95.64 million for the quarter, compared to analyst estimates of $82.24 million. GeneDx had a negative net margin of 17.12% and a positive return on equity of 3.33%. Research analysts expect that GeneDx will post 0.97 EPS for the current year.
GeneDx Company Profile
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
Featured Stories
- Five stocks we like better than GeneDx
- How to Choose Top Rated Stocks
- Can TikTok Stock Picks Really Make You Rich?
- What is a Dividend Harvesting Strategy and How Can Investors Profit from it?
- The “Quality” Rotation: Back to Basics Investing
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.